Nephrology
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Conference Coverage
Survival after kidney transplantation lags in diabetes patients
Overall U.S. survival after kidney transplantation rose during 2000-2018, but less so in patients with type 1 or type 2 diabetes.
From the Journals
Late-onset neutropenia more common than expected in patients on rituximab
“Even though most [cases] are incidental and can be self-limiting, some can be severe and associated with sepsis.”
From the Journals
Deaths sky high in hospitalized COVID patients with kidney injury
“We may be facing an epidemic of post–COVID-19 kidney disease and that, in turn, could mean much greater numbers of patients who require kidney...
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
Feature
SGLT2 inhibitors have a breakout year
Latest News
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
The findings are based on the use of three different SGLT2 inhibitors in Canada and the United Kingdom.
News
Terlipressin squeaks by FDA review for hepatorenal syndrome 1
The FDA advisory committee’s 8-7 vote favoring approval of terlipressin for hepatorenal syndrome type 1 reflected concerns and misgivings.
Conference Coverage
SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’
When the SGT2 inhibitor drugs first came to the U.S. market they were labeled for just treating hyperglycemia, but those days are over.
Feature
Dropping race-based eGFR adjustment gains traction in U.S.
“Race is a social, not a biological, construct and the kidney-function race multiplier ignores the substantial genetic diversity within self-...